GENMAB A/S DKK (GNMSF) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 12 111 sessions, October 22, 2025 to October 23, 2026
- Largest daily move
- +15.2% close of October 23, 2026
- 1-year change
- +50.6% closing prices, October 22, 2025 to October 23, 2026
- 1-month change
- +32.1% closing prices, September 23, 2026 to October 23, 2026
Company Description
Genmab A/S (GNMSF) is a foreign private issuer whose securities are associated with the ticker GNMSF. According to its regulatory disclosures, Genmab A/S files reports with the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934 as a non‑U.S. company. The company uses Form 6-K to furnish current reports and references multiple registration statements on Form S-8, indicating that it has registered securities for employee or related compensation plans.
In an SEC filing identified as a Form 6-K for the month of September 2025, Genmab A/S states that the report is furnished pursuant to Rule 13a-16 or 15d-16 of the Exchange Act. The filing also specifies that the Form 6-K is deemed to be incorporated by reference into several of the company’s existing Form S-8 registration statements. This linkage shows how Genmab A/S integrates its ongoing current reports into its broader U.S. securities registration framework.
Genmab A/S is based in Denmark, with its address in Valby, Denmark, as disclosed in the Form 6-K. The filing further notes that the company files annual reports under cover of Form 20-F or Form 40-F, and includes a check-box section for this purpose. This confirms that Genmab A/S follows the foreign issuer reporting regime rather than the domestic U.S. issuer framework.
The September 2025 Form 6-K includes an exhibit index listing a Company Announcement: Major Shareholder Announcement and a Standard form for notification of major holdings. This indicates that Genmab A/S provides market updates related to significant shareholdings and uses standardized notification formats for major holdings, which can be relevant for investors monitoring changes in substantial ownership positions.
Because the available information is drawn from a specific SEC filing, detailed information about the company’s industry, sector, products, or services is not provided here. Investors researching GNMSF can use this overview as a starting point to understand that Genmab A/S is a Denmark-based foreign issuer with securities registered in the United States and that it communicates major shareholder information through Form 6-K exhibits.
Stock Performance
GENMAB A/S DKK (GNMSF) closed at $447.55 on October 23, 2026. Over the past 12 months, the price has gained 50.6%.
GNMSF Metrics & Rankings
Price returns through October 23, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
SEC Filings
GENMAB A/S DKK has filed 10 recent SEC filings, including 9 Form 6-K, 1 Form SCHEDULE 13G. The most recent filing was submitted on October 23, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all GNMSF SEC filings →
Financial Highlights
GENMAB A/S DKK generated $3.7B in revenue in FY2025, retaining a 93.6% gross margin, operating income reached $1.1B (28.6% operating margin), and net income was $963.0M, reflecting a 25.9% net profit margin. Diluted earnings per share stood at $15.37. The company generated $1.2B in operating cash flow. The current ratio was 2.02, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in GENMAB A/S DKK (GNMSF) currently stands at 106.5 thousand shares, down 44.4% from the previous reporting period, representing 0.2% of the float.
Days to Cover History
Days to cover for GENMAB A/S DKK (GNMSF) currently stands at 296.6 days, up 526.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since October 2025, the figure has increased by 1386.7%. Across the settlements charted above, it has ranged from 3.4 to 1000.0 days.
GNMSF Company Profile & Sector Positioning
GENMAB A/S DKK (GNMSF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.